SYNC-T demonstrated high efficacy in resolving bone metastases in metastatic prostate cancer, achieving an 87% overall response rate in a phase 1 trial. The therapy involves a minimally-invasive ...

Casdatifan showed promising clinical activity in clear cell RCC, with response rates between 25% and 33% across dosage cohorts. The 100 mg/day dosage of casdatifan is planned for future combination ...

“No doubt about it, this is unequivocally a positive trial by the rPFS criteria. Quite positive,” says A. Oliver Sartor, MD. Results from the phase 3 PSMAfore (NCT04689828) trial indicate that ...

In patients with prostate cancer with biochemical recurrence following primary therapy, an intensified androgen blockade regimen consisting of apalutamide (Erleada) plus androgen deprivation therapy ...

"We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS. "The increasing expenses ...

DFS rate was 85.3% at 6 months (95% CI, 71.6-92.7), 74.3% at 12 months (95% CI, 59.2-84.6), and 69.2% at 18 months (95% CI, 53.4-80.6).

FDA clears stapler for use with da Vinci SP surgical system ...

To destigmatize testosterone deficiency, Justin Dubin, MD, advises clinicians on how to create a comfortable space for their patients and advises patients on how to be comfortable with talking about ...

"If a high percentage of the radicals are billed with urethral suspension, then it is likely to be bundled in the future and it is possible that it will be tagged with an indicator that will not allow ...

"We have over 30 years of safety data, and no adverse events in over 30 years," says Heather Florio. In this interview, Heather Florio and Stephen J. Walker, PhD, discuss the use of aloe vera in ...